Heartflow, Inc.

Overview

Heartflow, Inc. is a commercial-stage medical technology company that provides AI-powered, non-invasive diagnostic solutions for coronary artery disease (CAD). By transforming standard coronary computed tomography angiography (CCTA) scans into patient-specific 3D digital models, Heartflow enables clinicians to visualize and analyze coronary anatomy and physiology with high precision. The company’s technology integrates deep learning, medical computer vision, and computational fluid dynamics (CFD) to support personalized treatment planning and risk stratification.

Core Technology and Services

Heartflow’s flagship platform, Heartflow One, serves as an end-to-end cloud-based suite for cardiovascular assessment. Key capabilities include:

• Heartflow FFRCT Analysis: A non-invasive diagnostic tool that calculates fractional flow reserve to evaluate the functional significance of coronary artery stenoses.
• Roadmap™ Analysis: Automated anatomical visualization and grading tools designed to streamline clinical reading workflows.
• Plaque Analysis & Staging: Quantitative characterization of atherosclerotic plaque, providing clinicians with detailed insights into plaque volume and risk profiles.
• PCI Navigator: An interactive 3D simulation tool that assists interventional cardiologists in planning percutaneous coronary interventions (PCI) and virtual stent placement.

Clinical Impact and Reach

Founded in 2007 based on bioengineering research originating at Stanford University, Heartflow has established a significant clinical footprint. Its technology is utilized by over 1,800 clinical institutions globally and has been applied to more than 750,000 patient cases. The company maintains a robust evidence base, supported by over 625 peer-reviewed publications and landmark clinical trials such as PRECISE and the DECIDE registry. Heartflow is a publicly traded company listed on the Nasdaq Global Select Market under the ticker symbol HTFL.